申请人:Ciba-Geigy Corporation
公开号:US04898854A1
公开(公告)日:1990-02-06
The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represents optionally substituted 2-carboxypyrrolidinyl, 2-carboxy-2,5-dihydropyrrolyl, 2-carboxy-1,2,3,6-tetrahydropyridinyl, 2-carboxy-1,2,5,6-tetrahydropyridinyl, 2-carboxypiperidinyl, 2-carboxytetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, 2-carboxy-2,3-dihydroindolyl or 2-carboxyperhydroindolyl as described herein, and in each of which the carboxy group may be functionalized in form of a pharmaceutically acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene provided that A does not represent a direct bond when Y represents 2-carboxypyrrolidinyl; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.
本发明涉及式I的膦酸##STR1##其中膦酸基团的一个或两个酸性羟基可能以药用可接受的单酯或二酯的形式进行官能化;其中Y表示可选择取代的2-羧基吡咯啉基、2-羧基-2,5-二氢吡咯基、2-羧基-1,2,3,6-四氢吡啶基、2-羧基-1,2,5,6-四氢吡啶基、2-羧基哌啶基、2-羧基四氢喹啉基或2-羧基四氢喹啉基、2-羧基-2,3-二氢吲哚基或2-羧基四氢吲哚基,如本文所述,在其中羧基可能以药用可接受的酯或酰胺形式进行官能化;A表示直链键、较低烯基、较低烷基亚甲基或较低烷基,前提是当Y表示2-羧基吡咯啉基时,A不表示直链键;及其药用可接受的盐;它们对于治疗哺乳动物的神经系统疾病以及作为N-甲基-D-天冬氨酸敏感的兴奋性氨基酸受体的拮抗剂是有用的。